论文部分内容阅读
为在ＳＣＩＤ小鼠体内获得人免疫Ｂ淋巴细胞，将１２～１４周龄的胎儿肝细胞（１～２）×１０１０／Ｌ腹腔注射于ＳＣＩＤ小鼠，然后再分次接种肝癌细胞。用ＥＬＩＳＡ法于第４，５，６周连续检测ＳＣＩＤ－ｈｕ小鼠血清人ＩｇＧ；用免疫组化ＡＢＣ法检测各种组织中的人淋巴细胞。各实验小鼠均检测到人ＩｇＧ的存在，最高为３９１μｇ／Ｌ，且随时间的延长呈上升趋势。在ＳＣＩＤ－ｈｕ小鼠肝、脾及腹腔接种瘤组织的周边，可见人ＣＤ３＋和ＣＤ２０＋的淋巴细胞。上述结果表明，用人胎肝细胞移植可在ＳＣＩＤ小鼠体内获得人淋巴细胞，并对人肝癌细胞抗原产生免疫应答，分泌一定水平的抗人肝癌的抗体。提示：用人胎肝细胞在ＳＣＩＤ小鼠体内可建立人免疫系统的部分功能。
To obtain human immune B lymphocytes in SCID mice, 12-14 week old fetal liver cells (1 to 2)×1010/L were intraperitoneally injected into SCID mice, and then liver cancer cells were inoculated again. Serum human IgG in SCID-hu mice was continuously detected by ELISA at weeks 4, 5, and 6; human lymphocytes in various tissues were detected by immunohistochemical ABC method. The presence of human IgG was detected in all experimental mice, with a maximum of 391 μg/L, and it increased with time. Human CD3+ and CD20+ lymphocytes were observed around the liver, spleen, and abdominal inoculum of SCID-hu mice. The above results indicate that human fetal liver cells can be used to obtain human lymphocytes in SCID mice and produce an immune response to human hepatoma cell antigens, secreting a certain level of antibodies against human liver cancer. Tip: The use of human fetal liver cells in SCID mice can establish some of the functions of the human immune system.